Mon, Jul 28, 2014, 3:52 AM EDT - U.S. Markets open in 5 hrs 38 mins

Recent

% | $
Click the to save as a favorite.

Galena Biopharma, Inc. Message Board

  • indulgeron indulgeron Dec 17, 2012 9:43 AM Flag

    Nice article today . . .

    by Brian Nichols. Gale will prevail ( rhymes, huh ? ).

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Great article!

      Sentiment: Strong Buy

      • 2 Replies to k_wellman62
      • Galena Biopharma is currently trading with a market cap of $128 million, which represents a $32 million loss since the company announced data. Aside from the short-term volatility and its $1.90 price, most analysts are predicting a price anywhere between $3.00 and $6.00; but how does it get there?

        If Galena was to reach the top target of $6.00, it would be valued over $400 million. Not bad for a company that began the year as a $35 million company. ... Galena's 2012 movement and its expected 2013 gains are not unheard of and are obviously sought among the investment community.

      • Galena Biopharma is currently trading with a market cap of $128 million, which represents a $32 million loss since the company announced data. Aside from the short-term volatility and its $1.90 price, most analysts are predicting a price anywhere between $3.00 and $6.00; but how does it get there?

        If Galena was to reach the top target of $6.00, it would be valued over $400 million. Not bad for a company that began the year as a $35 million company. However, this is not an odd occurrence in this sector. There are countless companies, such as Inhibitex, Sarepta Therapeutics (SRPT), and Pharmacyclics (PCYC), that all saw similar valuations and rose with even larger gains in a shorter period of time. Therefore, Galena's 2012 movement and its expected 2013 gains are not unheard of and are obviously sought among the investment community.

        Sentiment: Strong Buy

    • Great article!

      -------------------------------

      Galena Biopharma is currently trading with a market cap of $128 million, which represents a $32 million loss since the company announced data. Aside from the short-term volatility and its $1.90 price, most analysts are predicting a price anywhere between $3.00 and $6.00; but how does it get there?

      If Galena was to reach the top target of $6.00, it would be valued over $400 million. Not bad for a company that began the year as a $35 million company. However, this is not an odd occurrence in this sector. There are countless companies, such as Inhibitex, Sarepta Therapeutics, and Pharmacyclics, that all saw similar valuations and rose with even larger gains in a shorter period of time. Therefore, Galena's 2012 movement and its expected 2013 gains are not unheard of and are obviously sought among the investment community.

      Sentiment: Strong Buy

    • Great article.

      Galena Biopharma is currently trading with a market cap of $128 million, which represents a $32 million loss since the company announced data. Aside from the short-term volatility and its $1.90 price, most analysts are predicting a price anywhere between $3.00 and $6.00; but how does it get there?

      If Galena was to reach the top target of $6.00, it would be valued over $400 million. Not bad for a company that began the year as a $35 million company. However, this is not an odd occurrence in this sector. There are countless companies, such as Inhibitex, Sarepta Therapeutics (SRPT), and Pharmacyclics (PCYC), that all saw similar valuations and rose with even larger gains in a shorter period of time. Therefore, Galena's 2012 movement and its expected 2013 gains are not unheard of and are obviously sought among the investment community.

      Sentiment: Strong Buy

    • Yes indeed.

      --------------------------------------------

      Galena Biopharma is currently trading with a market cap of $128 million, which represents a $32 million loss since the company announced data. Aside from the short-term volatility and its $1.90 price, most analysts are predicting a price anywhere between $3.00 and $6.00; but how does it get there?

      If Galena was to reach the top target of $6.00, it would be valued over $400 million. Not bad for a company that began the year as a $35 million company. However, this is not an odd occurrence in this sector. There are countless companies, such as Inhibitex, Sarepta Therapeutics (SRPT), and Pharmacyclics (PCYC), that all saw similar valuations and rose with even larger gains in a shorter period of time. Therefore, Galena's 2012 movement and its expected 2013 gains are not unheard of and are obviously sought among the investment community.

      Sentiment: Strong Buy

 
GALE
2.940.00(0.00%)Jul 25 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Puma Biotechnology, Inc.
NYSEFri, Jul 25, 2014 4:01 PM EDT
Sohu.com Inc.
NasdaqGSFri, Jul 25, 2014 3:59 PM EDT